S&P 500   4,963.00 (-0.25%)
DOW   38,514.15 (-0.13%)
QQQ   423.69 (-0.85%)
AAPL   181.46 (-0.06%)
MSFT   399.14 (-0.91%)
META   467.07 (-0.89%)
GOOGL   142.44 (+0.94%)
AMZN   167.91 (+0.50%)
TSLA   192.93 (-0.43%)
NVDA   669.65 (-3.58%)
NIO   6.04 (+1.34%)
AMD   163.61 (-1.26%)
BABA   75.92 (+3.80%)
T   16.97 (+0.35%)
F   12.11 (-1.14%)
MU   80.59 (-0.15%)
CGC   3.39 (-4.24%)
GE   148.27 (-0.24%)
DIS   107.82 (-1.48%)
AMC   4.58 (-1.72%)
PFE   27.51 (-0.29%)
PYPL   57.54 (-1.86%)
XOM   104.72 (+1.92%)
S&P 500   4,963.00 (-0.25%)
DOW   38,514.15 (-0.13%)
QQQ   423.69 (-0.85%)
AAPL   181.46 (-0.06%)
MSFT   399.14 (-0.91%)
META   467.07 (-0.89%)
GOOGL   142.44 (+0.94%)
AMZN   167.91 (+0.50%)
TSLA   192.93 (-0.43%)
NVDA   669.65 (-3.58%)
NIO   6.04 (+1.34%)
AMD   163.61 (-1.26%)
BABA   75.92 (+3.80%)
T   16.97 (+0.35%)
F   12.11 (-1.14%)
MU   80.59 (-0.15%)
CGC   3.39 (-4.24%)
GE   148.27 (-0.24%)
DIS   107.82 (-1.48%)
AMC   4.58 (-1.72%)
PFE   27.51 (-0.29%)
PYPL   57.54 (-1.86%)
XOM   104.72 (+1.92%)
S&P 500   4,963.00 (-0.25%)
DOW   38,514.15 (-0.13%)
QQQ   423.69 (-0.85%)
AAPL   181.46 (-0.06%)
MSFT   399.14 (-0.91%)
META   467.07 (-0.89%)
GOOGL   142.44 (+0.94%)
AMZN   167.91 (+0.50%)
TSLA   192.93 (-0.43%)
NVDA   669.65 (-3.58%)
NIO   6.04 (+1.34%)
AMD   163.61 (-1.26%)
BABA   75.92 (+3.80%)
T   16.97 (+0.35%)
F   12.11 (-1.14%)
MU   80.59 (-0.15%)
CGC   3.39 (-4.24%)
GE   148.27 (-0.24%)
DIS   107.82 (-1.48%)
AMC   4.58 (-1.72%)
PFE   27.51 (-0.29%)
PYPL   57.54 (-1.86%)
XOM   104.72 (+1.92%)
S&P 500   4,963.00 (-0.25%)
DOW   38,514.15 (-0.13%)
QQQ   423.69 (-0.85%)
AAPL   181.46 (-0.06%)
MSFT   399.14 (-0.91%)
META   467.07 (-0.89%)
GOOGL   142.44 (+0.94%)
AMZN   167.91 (+0.50%)
TSLA   192.93 (-0.43%)
NVDA   669.65 (-3.58%)
NIO   6.04 (+1.34%)
AMD   163.61 (-1.26%)
BABA   75.92 (+3.80%)
T   16.97 (+0.35%)
F   12.11 (-1.14%)
MU   80.59 (-0.15%)
CGC   3.39 (-4.24%)
GE   148.27 (-0.24%)
DIS   107.82 (-1.48%)
AMC   4.58 (-1.72%)
PFE   27.51 (-0.29%)
PYPL   57.54 (-1.86%)
XOM   104.72 (+1.92%)
NASDAQ:PRTA

Prothena (PRTA) Stock Price, News & Analysis

$26.87
-0.66 (-2.40%)
(As of 01:25 PM ET)
Today's Range
$26.60
$27.86
50-Day Range
$25.05
$40.66
52-Week Range
$24.28
$79.65
Volume
194,784 shs
Average Volume
981,660 shs
Market Capitalization
$1.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$69.89

Prothena MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
161.9% Upside
$69.89 Price Target
Short Interest
Healthy
10.71% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Prothena in the last 14 days
Based on 27 Articles This Week
Insider Trading
Selling Shares
$525,950 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.97) to ($3.83) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.72 out of 5 stars

Medical Sector

250th out of 932 stocks

Pharmaceutical Preparations Industry

115th out of 431 stocks


PRTA stock logo

About Prothena Stock (NASDAQ:PRTA)

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

PRTA Stock Price History

PRTA Stock News Headlines

Prothena (NASDAQ:PRTA) Stock Rating Lowered by StockNews.com
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
JMP Securities Boosts Prothena (NASDAQ:PRTA) Price Target to $85.00
PRTA Mar 2024 105.000 call
Prothena Full Year 2023 Earnings: Beats Expectations
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
RBC Capital Reaffirms Their Hold Rating on Prothena (PRTA)
Decoding 6 Analyst Evaluations For Prothena Corp
Prothena Co. plc (NASDAQ:PRTA) Sees Large Decline in Short Interest
Earnings Outlook For Prothena Corp
Navigating 5 Analyst Ratings For Prothena Corp
Demystifying Prothena Corp: Insights From 5 Analyst Reviews
Prothena Corp PLC PRTA
See More Headlines
Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
2/21/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRTA
Employees
127
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$69.89
High Stock Price Target
$90.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+160.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

Net Income
$-147,030,000.00
Net Margins
-160.91%
Pretax Margin
-61.37%

Debt

Sales & Book Value

Annual Sales
$91.37 million
Book Value
$12.86 per share

Miscellaneous

Free Float
38,531,000
Market Cap
$1.44 billion
Optionable
Optionable
Beta
0.25
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report














PRTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Prothena stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PRTA shares.
View PRTA analyst ratings
or view top-rated stocks.

What is Prothena's stock price target for 2024?

10 analysts have issued 12 month price targets for Prothena's stock. Their PRTA share price targets range from $35.00 to $90.00. On average, they expect the company's stock price to reach $69.89 in the next year. This suggests a possible upside of 161.9% from the stock's current price.
View analysts price targets for PRTA
or view top-rated stocks among Wall Street analysts.

How have PRTA shares performed in 2024?

Prothena's stock was trading at $36.34 on January 1st, 2024. Since then, PRTA shares have decreased by 26.6% and is now trading at $26.69.
View the best growth stocks for 2024 here
.

Are investors shorting Prothena?

Prothena saw a drop in short interest in the month of January. As of January 31st, there was short interest totaling 5,750,000 shares, a drop of 8.1% from the January 15th total of 6,260,000 shares. Based on an average daily trading volume, of 845,900 shares, the short-interest ratio is presently 6.8 days.
View Prothena's Short Interest
.

When is Prothena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our PRTA earnings forecast
.

How were Prothena's earnings last quarter?

Prothena Co. plc (NASDAQ:PRTA) announced its earnings results on Thursday, February, 15th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($1.23) by $0.03. The biotechnology company earned $0.32 million during the quarter, compared to the consensus estimate of $2.15 million. Prothena had a negative net margin of 160.91% and a negative trailing twelve-month return on equity of 24.42%. Prothena's revenue for the quarter was down 99.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.12 earnings per share.

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

Who are Prothena's major shareholders?

Prothena's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (7.90%), Price T Rowe Associates Inc. MD (7.90%), Palo Alto Investors LP (3.09%), First Light Asset Management LLC (2.03%), Vanguard Group Inc. (1.99%) and Dimensional Fund Advisors LP (1.62%). Insiders that own company stock include Brandon S Smith, Carol D Karp, Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker, Lars Ekman, Michael J Malecek, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen, Wagner M Zago and Wagner M Zago.
View institutional ownership trends
.

How do I buy shares of Prothena?

Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRTA) was last updated on 2/21/2024 by MarketBeat.com Staff